Navigation Links
Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
Date:9/13/2009

oster #141: "Comparative bioavailability of NKTR-118 tablets and solution: a case of bioequivalence between dosage forms for a rapidly absorbed drug"

The corresponding abstracts for these presentations are published in the September 2009 issue of The Journal of Clinical Pharmacology (J. Clin. Pharmacol., Sept 2009; 49:1123).

About Opioid-Induced Constipation

The oral peripheral antagonist NKTR-118 targets mu-opioid receptors within the enteric nervous system, which mediate opioid-induced bowel dysfunction, a symptom complex resulting from opioid use that encompasses symptoms such as constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome and is generally its most prominent component. In patients who take opiates chronically for pain management, anywhere from 45-90% of patients will develop debilitating constipation associated with other symptoms of opioid-induced bowel dysfunction as a result of the drug binding to the mu-opioid receptor in the gut(1).

According to IMS Health, about 230 million prescriptions were written for opioids in 2007 in the United States alone. Currently, there are no oral drugs approved that are indicated to treat opioid-induced constipation (OIC). Opioid bowel dysfunction and OIC can significantly impact quality of life and increase healthcare utilization.

Nektar is also developing NKTR-119, an investigational drug candidate that is a co-formulation of oral NKTR-118 and an opioid analgesic. The product is designed to provide good analgesic properties in the chronic treatment of moderate to severe pain patients while avoiding the debilitating side effects that are common with opioid use, such as constipation and other symptoms of bowel dysfunction.

About Nektar

Nektar Therapeutics is a biop
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... INDIANAPOLIS , June 18, 2013   ... partnership with Aegis Health Group to ... Aegis workforce wellness programs administered by health systems ... system, manufactured by PTS and distributed through ... for total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, ...
(Date:6/17/2013)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... 2013, the Endocrine Society,s 95 th Annual ... melatonin and cortisol rhythms. This effect further confirms ... and address the circadian desynchrony which is inherent ... Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of ...
(Date:6/17/2013)... 2013 DNAtrix Inc., experts in oncolytic virus ... data on the company,s lead product, DNX-2401, at the ... City, Canada on June 18, 2013. ... a leader in the field of oncolytic virus therapy, ... PHASE I TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 ...
Breaking Medicine Technology:Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2
(Date:6/18/2013)... SEATTLE, WA—A Washington state resident filed a lawsuit ... fell ill with a hepatitis A infection after eating ... The complaint was filed in Snohomish County Superior Court ... firm that has filed 14 previous lawsuits against ... Brothers consumed “Townsend Farms Organic Antioxidant Blend” on multiple ...
(Date:6/18/2013)... Horsham, PA (PRWEB) June 18, 2013 Senior ... in Boston on June 25 to discuss—for the first time ... agencies in getting drugs through the regulatory process in a ... of drug evaluation will share respective best practices and processes ... Across the Strait panel at the DIA 2013 ...
(Date:6/18/2013)... Sun Buick GMC, Moosic, is sponsoring the hole-in-one contest at ... on Thursday, June 20, at Irem Country Club, Dallas, Pennsylvania. ... Verano and will go to the lucky golfer at the ... , The MFHS golf tournament is open to all interested ... crew team for 18 holes. The fee is $125 per ...
(Date:6/18/2013)... Center clinical researchers have launched an innovative clinical ... the ability of a patient,s own stem cells ... arterial disease (PAD). , Led by Vik ... Hospitals Case Medical Center,s Harrington Heart & Vascular ... Reserve University School of Medicine, the clinical trial ...
(Date:6/18/2013)... The July 2013 issue of Marie Claire ... Beach Ready,” offers a list of home and doctor’s office ... a bathing suit this summer. The list includes treatment options ... smoothing cellulite , and more. (go to goo.gl/aIe4J). , “It’s ... Epione Beverly Hills, “though I would say some of the ...
Breaking Medicine News(10 mins):Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Skin Care – Getting Your Body Beach Ready 2
... with Attention Deficit Hyperactivity Disorder - ADHD - ... with decision-making, thinking and planning. The abnormality was ... researchers to look at the brains of children ... of Child Psychiatry at the Medical Research Council, ...
... and Drug Administration agreed that an ingredient commonly used ... recommend further review by the FDA. ,The FDA ... five-year study by Yale University researchers that found phenyl-propanolamine ... the risk of stroke in some users. PPA helps ...
... a degenerative brain disease that usually begins gradually, ... familiar tasks. The disease eventually leads// to confusion, ... becomes more difficult as the disease progresses, leaving ... or follow directions. Eventually, most people with Alzheimer’s ...
... way to predict when somebody is likely to have ... occur suddenly and without warning and can lead to ... de la Pitie-Salpetriere, Paris, believe ,it may be possible ... an electroencephalogram ,(EEG). ,An ECG records electrical activity ...
... may allow treatment at a later stage than other ... the market for a decade in Germany// and was ... of the Food and Drug Administration. ... approved Alzheimer's drugs, such as Aricept, that have been ...
... Women are more prone to get depression during their pregnancy ... for depression was 32 weeks// into pregnancy, close to birth. ... a rise in stress hormones could lead to low birth ... the Avon area, whose babies were due between April 1 ...
Cached Medicine News:
... designed specifically for the Palm Organizers ... ward rounds. It is intended to ... consultations that are requested by the ... Ward round examinations and to record ...
... tracking and billing. This ... Handheld application, a complete ... CPT™ and ICD-9-CM codes ... Designed for any medical ...
In addition to the patient data OB-on-Call contains a comprehensive Medications list displaying related drugs by brand name, generic title, and usage description notes....
Archimedes is an innovative specialty calculator. Forget having to remember complicated formulas, just enter the values and out come the results....
Medicine Products: